Serplulimab with cryoablation for early-stage lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of a drug that helps your immune system fight cancer (serplulimab) and a procedure that freezes and destroys cancer cells (cryoablation) for people with early-stage non-small cell lung cancer who cannot or choose not to have surgery or radiation. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of early-stage non-small cell lung cancer (tumor size between 1 cm and 3 cm) that has not spread to lymph nodes or other parts of the body.
- Your cancer must not have certain genetic changes (EGFR, ALK, or ROS1) that are often targeted by other drugs.
- You must not be able or willing to have surgery or radiation, as decided by a team of doctors.
- You must have at least one tumor that can be measured and used to track response.
- You must be in generally good health, with adequate organ function (kidney, liver, blood counts) and a life expectancy of at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (toripalimab) and a freezing treatment (cryoablation) for people with advanced non-small cell lung cancer that has started to grow again in only a few spots after initial treatment. It aims to see if this approach can help control the cancer without switching to a completely new therapy.
This Phase 2 study looks at how safe and effective serplulimab (an immune medicine) combined with chemotherapy is when used as a “conversion” plan—first shrinking lung cancer, then trying to remove the main tumor with surgery. It may help some people who are not initially good candidates for surgery or focused radiation to become eligible after treatment.
This study tests a new way to freeze and destroy small lung tumors using a thin tube with a camera (bronchoscope) to guide the freezing probe. It is for people with early-stage lung cancer or limited lung metastases who cannot or prefer not to have surgery or radiation.
This trial tests a treatment for early-stage lung cancer (stage I-IIA) that uses extreme cold to freeze and destroy the tumor, called cryoablation. Some patients will also receive an immunotherapy drug called serplulimab, which helps the immune system fight the cancer, to see if adding it improves outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab), chemotherapy, and a procedure called cryoablation (freezing the tumor) for people with a type of lung cancer called non-small cell lung cancer that has spread or come back. The goal is to see if this combination is safe and effective.
This study tests a new approach for people with early-stage lung cancer that can be removed with surgery. Before surgery, patients receive a treatment called cryo-thermal ablation to freeze and heat the tumor, along with an immunotherapy drug (toripalimab) and chemotherapy. The goal is to see if this combination shrinks tumors and improves outcomes after surgery.
Hear when a new Early Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.